Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
about
Is autoimmunity the Achilles' heel of cancer immunotherapy?Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab.New-onset insulin-dependent diabetes due to nivolumab.
P2860
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@en
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@nl
type
label
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@en
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@nl
prefLabel
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@en
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@nl
P2093
P2860
P921
P1476
Genetic risk analysis of a pat ...... b and nivolumab immunotherapy.
@en
P2093
April K S Salama
Clayton E Mathews
Daniel J Perry
Jared R Lowe
Larry G Moss
P2860
P2888
P356
10.1186/S40425-016-0196-Z
P577
2016-12-20T00:00:00Z
P6179
1025492514